An influential doctor who spent decades studying and treating lung conditions has died of acute respiratory distress syndrome, or ARDS, caused by COVID-19,University of California, San Francisco ...

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Update on EB05 Development in ARDS Edesa Biotech, Inc. (NASDAQ:EDSA) is developing EB05 (paridiprubart) as a ...

The randomized, double-blind, placebo-controlled trial will compare the efficacy and safety of siltuximab, an interleukin-6 (IL-6) antagonist, to placebo, plus standard of care, in approximately ...

ARDS has long been recognized to be remarkably heterogeneous, with not only a wide range of causes but also a broad spectrum of severity, abnormalities on imaging, and gas-exchange impairment. 1 ...

Among those with both ARDS and PH, 36.8% died in the hospital, which was higher than the in-hospital mortality rate of 24.6% observed among those with ARDS and without PH.

BioAegis Therapeutics. Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS ...

Among the 740 patients who were admitted to the ICU after cardiac surgery during baseline periods, ARDS developed in 38 (5.1%). In the periods between baseline and influenza seasons, ARDS ...

Of the more than 13,000 children who survived acute respiratory distress syndrome (ARDS), there was a 30.0% probability of hospital readmission within 1 year, 50% of which are likely to occur ...

The incidence of ARDS has often been described as highly variable, depending on the type of ICU (eg, medical, surgical, trauma, burn) and type of hospital (large tertiary referral vs small ...

In ARDS, the circulating half-life of methylprednisolone (1 mg/kg) varies from 3.8 to 7.2 h, with greatly diminished effects (irrespective of dosage) expected after 24 to 36 h.